Cellectis (NASDAQ:CLLS – Get Free Report) and NKGen Biotech (NYSE:NKGN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.
Profitability
This table compares Cellectis and NKGen Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cellectis | -234.39% | -74.55% | -22.65% |
| NKGen Biotech | N/A | N/A | -479.36% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Cellectis and NKGen Biotech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cellectis | 0 | 0 | 3 | 0 | 3.00 |
| NKGen Biotech | 0 | 0 | 0 | 0 | 0.00 |
Earnings and Valuation
This table compares Cellectis and NKGen Biotech”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cellectis | $9.19 million | 11.73 | -$101.06 million | ($1.30) | -1.49 |
| NKGen Biotech | $80,000.00 | 131.50 | -$82.94 million | ($5.08) | -0.06 |
NKGen Biotech has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
63.9% of Cellectis shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 74.7% of NKGen Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
Cellectis has a beta of 3.1, meaning that its share price is 210% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.
Summary
Cellectis beats NKGen Biotech on 7 of the 13 factors compared between the two stocks.
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
About NKGen Biotech
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.
